Humanitas Global Health launched at AAPS PharmSci 360 with LSU’s DeepDrug, which pairs an LLM with a hypergraph for drug design and prescription safety.
NIH is reorganizing clinical trial funding by trial type instead of disease
The National Institutes of Health (NIH) is planning a suite of five cross-institute trial Notices of Funding Opportunity (NOFOs) that it says would give investigators one set of instructions per trial type. On Nov. 10, NIH said its institutes are jointly building broad clinical trial NOFOs organized by trial type. Historically, many institutes wrote their…
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Design
by Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator safety. Among the many variables that must be tightly controlled, pressure ranks high on the list. Overpressure or vacuum conditions can compromise not only equipment, but also batch sterility, production timelines, and…
Unlocking PROTAC potential through better delivery
PROTACs (proteolysis-targeting chimeras) are an emerging class of drug molecules designed to eliminate disease-causing proteins rather than simply block them. Each PROTAC has two binding ends joined by a chemical linker: one end attaches to the target protein, while the other recruits an E3 ubiquitin ligase, an enzyme that tags proteins for disposal. By bringing…
Psychedelic pioneer Compass files for FDA approval as rivals close in
Compass Pathways completed its NDA for COMP360 psilocybin in treatment-resistant depression as Usona, Definium and other psychedelic developers advance.
FDA’s GLP-1 vision warning rests on mixed evidence
The FDA is requiring all GLP-1 drug labels to carry a NAION warning, though trial and observational data on the eye-stroke risk are mixed.
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
Insilico’s AI-designed pan-TEAD inhibitor ISM6331 produced responses in 4 of 22 pretreated mesothelioma patients; a Phase 2a is planned for 2027.
Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3
Moderna is preparing to seek approval for intismeran autogene, the personalized cancer vaccine it is developing with Merck, according to its November 6 earnings release. The therapy could open a new source of revenue beyond the infectious disease vaccines that built its business. Investor enthusiasm has rebounded as the cancer program has advanced. Moderna shares…
From cost advantage to value advantage: The next frontier for generic manufacturers
For more than three decades, generic drugmakers competed on a simple formula: enter fast, manufacture at scale and cut costs. Generics and biosimilars saved the U.S. healthcare system $496 billion in 2025, according to the Association for Accessible Medicines’ 2026 savings report. That formula is now under strain. Purchasers have consolidated, prices face pressure, much…
FDA approved Inovio’s Voceryq with open questions about its delivery device
The FDA has asked Inovio Pharmaceuticals, a company developing DNA-based medicines, to reanalyze its human factors testing of the Cellectra 5PSP, the electroporation device that delivers its newly approved drug Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), a pioneering plasmid DNA-based immunotherapy. The agency is also asking it to verify the device’s sharps injury prevention feature.…
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Drug prices are one of the few issues on which Donald Trump has found common ground with progressive Democrats, and with voters in both parties. A March 2026 KFF poll found that 72% of adults say there is not enough government regulation limiting drug prices, including 77% of Democrats, 72% of independents and 68% of…
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Fresenius gets option rights on up to 37 first-to-market biosimilar candidates developed by WuXi Biologics, starting with copies of Roche’s Polivy and Amgen’s Tepezza. Fresenius picks the programs and keeps the economics; WuXi Biologics builds them for a per-program fee.
What real-world data shows about current cancer care
Only about 5% of adult cancer patients join clinical trials. Experts explain how real-world data fills gaps and what makes it representative and reliable.
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
Roche picks the targets and Hansoh builds the ADCs under a deal with $400 million upfront, a $110 million first-anniversary payment and more than $15 billion in milestones. The split mirrors AstraZeneca’s January deal with CSPC.
The FDA plans its third rare disease policy change in just over a year
On Oct. 14, the FDA announced a plan called the “Rare Disease Framework Initiative,” described in a new white paper, to build a “fit-for-purpose” approach to reviewing drugs and biologics for rare diseases. The FDA says the initiative aims to give developers of rare disease treatments clearer, more consistent guidance on the evidence needed for…
AAPS names Patrick Sinko chief science officer
The American Association of Pharmaceutical Scientists (AAPS) has named Patrick J. Sinko, Ph.D., R.Ph., as chief science officer. Sinko will set the organization’s scientific strategy, guide scientific programming across in-person and digital platforms, and guide the direction of AAPS’s portfolio of peer-reviewed journals. Sinko, a pharmacist and pharmaceutical scientist, retains his academic appointment at Rutgers,…
Digital pathology’s next act: Mining old tissue to spare future animal studies
The field of digital pathology went from a specialist interest to a practical necessity during the pandemic, when many pathologists couldn’t get to the microscope. Digitizing slides let them keep working remotely. Since then, researchers have developed ways to extract more information from those images, including patterns linked to molecular changes in tissue. Traditionally, the…
AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists
AAPS PharmSci 360 delivers research spanning the pharmaceutical product lifecycle. Thousands of scientists and leaders, representing large and small pharma from across the globe converge at this science-first event to discuss cutting-edge approaches and technologies. Sessions and posters highlight recent innovations that can benefit early-stage researchers. RX-360, AstraZeneca, Mayo Clinic, and Merck are just some…
Pharma tariffs reach smaller drugmakers as industry warns of R&D pressure
After more than a year of threats and six months after President Donald Trump signed a national-security proclamation, U.S. tariffs on imported patented medicines and their ingredients expanded Sept. 29 to mid-sized and smaller drugmakers that were left off the first company list. Duties that began July 31 for 17 large manufacturers now apply to…
‘A plate of spaghetti’: Talus Bio boasts 5,000-fold faster drug screening by skipping protein folding
Few software releases have shaken drug discovery like AlphaFold. Its creators shared a Nobel Prize, and its public database put predicted structures for more than 200 million proteins open to researchers worldwide. Turning those structures into drugs poses another set of problems. Seattle-based Talus Bio is going after proteins that resist that approach, notably transcription…
Alphabet and Meta now spend nearly as much on R&D as pharma’s 10 largest drugmakers
Google parent Alphabet and Meta reported a combined $118.5 billion in R&D expense for 2025, close to the $123.7 billion spent by the 10 largest drugmakers by revenue, a figure that includes J&J’s medtech and Roche’s diagnostics units. While Big Tech’s R&D budgets keep swelling, Big Pharma is aligning itself with Big Tech firms. In…
Pharma commercial vendor selection still runs on word of mouth. A Harvard MBA student aims to change that with Rx Almanac.
For pharma companies preparing to launch a drug or expand commercial operations, choosing vendors for distribution, pricing, and customer relationship management is a world away from comparing common business software. Buyers of mainstream business software can consult reviews on the software comparison sites G2 and Gartner Peer Insights, along with analyst evaluations such as the…
After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
The magic mushroom compound psilocybin, which has had favorable results in two Phase 3 trials of depression and could be available as soon as 2027, has shown promise in rodents as a potential preventative for Chemotherapy‑Induced Peripheral Neuropathy (CIPN), a disabling pain condition caused by chemotherapy that affects about 30% to 50% of patients receiving chemotherapy. A 2014 review found that 68.1% of chemotherapy patients across 31 studies had CIPN when measured in…
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
On August 25-26, the U.S. Drug Enforcement Administration (DEA) followed up on two Federal Register notices published on July 1 that signaled its intent to temporarily place several synthetic alkaloids associated with Mitragyna speciosa (commonly known as kratom leaf or kratom) in Schedule I of the Controlled Substances Act (CSA). One notice concerned three synthetic…
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice
The COVID-19 pandemic left most of the world’s population with an immune memory for COVID. A Cleveland-based biotech wants to use that memory to fight cancer. Celloram, a preclinical stage company focusing on therapies for cancer, autoimmune diseases and chronic inflammatory and metabolic disorders, in partnership with Case Western Reserve University and University Hospitals Cleveland Medical Center, published preclinical results for a…
























